TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05487391: QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection: a Randomized,

Sponsor: Qilu Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 632 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT05487391 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05487391 Rescue Dossier →